Halobetasol/tazarotene (Duobrii) is a topical combination drug used to treat plaque psoriasis. It combines 0.01% halobetasol propionate and 0.045% tazarotene in a lotion formulation. It was approved as a prescription drug by the U.S. Food and Drug Administration (FDA) in April 2019 and by Health Canada in June 2020.